在胰腺癌中免疫抵抗的分子机制:更新
Wei Ming Pang1, Wei Meng Lim2, Zi Ni Ngai3
1School of Health Sciences, IMU University, 57000 Kuala Lumpur, Malaysia.
Current pharmaceutical biotechnology
|April 16, 2025
概括
胰腺癌由于其瘤微环境和分子通路而发展出显著的免疫抵抗力. 了解这些机制对于开发有效的免疫疗法来治疗这种侵袭性疾病至关重要.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 胰腺癌是高度侵略性的,预后不佳,主要是由于免疫抵抗.
- 胰腺癌中的瘤微环境 (TME) 富含着肌和免疫抑制因素.
- 尽管进行了研究,但胰腺癌免疫抵抗的分子机制仍然不完全理解.
研究的目的:
- 审查胰腺癌中免疫抵抗的基础分子机制.
- 探索TME如何在胰腺癌中促进免疫逃避.
- 确定潜在的治疗策略,以克服免疫障碍.
主要方法:
- 在胰腺癌中免疫抵抗的分子机制的文献综述.
- 分析瘤微环境 (TME) 和免疫抑制因素的作用.
- 检查致癌途径和免疫抑制细胞群的检查.
主要成果:
- TME通过PD-L1,IDO,腺和氨等因素抑制抗瘤免疫力.
- 致癌途径 (TP53,KRAS) 和免疫抑制细胞 (T-regs,MDSCs) 诱导免疫抵抗.
- 包括PD-L1介导的MHC-1下调和P2RX1-阴性中性粒细胞在内的机制有助于免疫逃避.
结论:
- 消除胰腺癌的免疫抵抗机制对于有效的免疫疗法开发至关重要.
- 针对TME和特定的分子通路提供了潜在的治疗途径.
- 克服免疫抵抗对于改善胰腺癌患者治疗结果至关重要.
更多相关视频
06:16Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity
Published on: December 7, 2019
12.5K
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
492
相关概念视频
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Cytotoxic T Cells-mediated Immune Response
720
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
720
Tumor Immunotherapy
397
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
397
Metastasis
5.4K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.4K
